ArticleTrials2022

Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial.

Nakwon Kwak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.